# Compare GLOW Blend and GHK-Cu — Lumira Peptides

> A side-by-side comparison of the GLOW research blend and its constituent GHK-Cu across peptide class, evidence base, regulatory status, WADA standing, and key cautions.

Where the two subjects on this desk converge, where they diverge, and how far the evidence behind each one actually reaches.

## The short version

This page lines up the [GLOW research blend](/glow) and [GHK-Cu](/ghk-cu) on the dimensions that matter most when reading peptide research: what kind of subject each one is, where it has been studied, how strong that evidence is, its regulatory standing, and the one caution that most defines it. The headline is direct. GHK-Cu is a well-characterized single peptide with decades of topical cosmetic use and the most human evidence of the two subjects here. The GLOW blend is a combination preparation whose constituents each carry their own literature, but whose blend-level evidence consists of zero controlled studies in any species [1][2]. Both are presented here as what the literature says, not as recommendations.

## Comparison matrix

| Dimension | GLOW (research blend) | GHK-Cu |
| --- | --- | --- |
| What it is | Co-formulated combination of GHK-Cu + BPC-157 + TB-500 (three distinct peptides) | Copper-binding tripeptide (3 aa) — Gly-His-Lys chelated to Cu(II) |
| Primary research territory | Skin remodeling + tissue repair + angiogenesis (combined constituent rationale) | Skin matrix synthesis, collagen/elastin stimulation, hair follicle biology |
| Evidence base | Individual constituents vary widely; blend itself: zero controlled studies [1][2] | Multiple small human topical trials; 1 RCT for hair (combination); in vitro + ex vivo |
| Evidence in humans | BPC-157: 3 tiny pilots [2]; GHK-Cu: topical dermatology trials; TB-500 fragment: none | Topical procollagen/skin-firmness in clinical comparisons; 45-patient hair-loss RCT [10] |
| FDA status | Not approved; BPC-157 not compounding-eligible per FDA; combination product is untested | No approved drug; topical Copper Tripeptide-1 is a legal cosmetic ingredient [8] |
| WADA status | Prohibited — TB-500 (S2, peptide hormones/growth factors) and BPC-157 both banned [1][2] | Not specifically listed; WADA S0 catch-all may apply — verify current list |
| Key caution | Blend is untested as a combined preparation; constituent kinetics are mismatched [1] | Poor skin permeability in native form; injectable/systemic use has no validated human PK [8] |

## What kind of subject each one is

The most fundamental difference is structure. GHK-Cu is a *defined single molecule* with a known structure, a CAS number, a long cosmetic ingredient history, and peer-reviewed literature going back decades [4]. The GLOW blend is a *multi-component preparation* — not a drug or a defined ingredient, but a combination formulated by suppliers and clinics whose ratios are not standardized and whose combined behavior has not been studied. This distinction matters for reading everything that follows: every finding cited for the GLOW blend actually belongs to one of its three constituents, not to the combination.

Within the blend, GHK-Cu is the matrix-and-radiance arm, BPC-157 is the pro-angiogenic arm, and the TB-500 fragment is the cell-migration arm — each studied separately, in different models, at different stages of human evidence [1][3][7].

## Evidence base and human data

GHK-Cu's topical evidence is the deepest of any peptide on this desk. Controlled comparisons have shown procollagen synthesis improvement in 70% of treated subjects, outperforming vitamin C (50%) and retinoic acid (40%), with documented placebo-controlled improvements in skin laxity, fine lines, and wrinkle depth [4]. A 6-month RCT with 45 men showed statistically significant hair-count increases with a GHK-containing combination topical versus placebo [10]. Ex vivo human skin-penetration work has quantified the copper depot formed in the dermis [11].

The GLOW blend as a whole has no controlled human evidence. For BPC-157, the most data-poor blend constituent in humans, only three small pilot studies exist — none powered or designed for efficacy [2]. For the TB-500 fragment (as distinct from the full thymosin beta-4 protein), controlled human data are essentially absent [1]. GHK-Cu is the best-evidenced leg of the tripod, which is why this desk treats it as the skin-rationale anchor.

## Regulatory and WADA standing

GHK-Cu is an unusual case: topical Copper Tripeptide-1 is a legal cosmetic ingredient in major markets, routinely used in serums, creams, and aftercare products, with a long safety record in that form [8]. Systemic or injectable GHK-Cu is a different matter — unapproved and research-only with no validated human pharmacokinetics.

The GLOW blend's regulatory picture is more restrictive because of its other two constituents. BPC-157 is not FDA-approved and was classified in 2023 as not eligible for pharmacy compounding pending evaluation [2]. TB-500 is the WADA-prohibited element: as the synthetic actin-binding fragment of thymosin beta-4, which appears on the WADA Prohibited List under S2 (peptide hormones, growth factors, related substances, and mimetics), the blend is off-limits for any tested athlete [1]. BPC-157 is also prohibited. This applies regardless of a user's intent or which constituent they believe is driving effects.

## Key cautions compared

For **GHK-Cu**, the defining caution is *delivery and scope*: poor skin permeability in native form limits how much of the topical evidence translates to systemic use; no validated human pharmacokinetics exist for injectable GHK-Cu; and the broader anti-aging gene-expression claims come largely from one research group and await independent protein-level validation [8][9].

For the **GLOW blend**, the defining caution is *the absence of blend-level evidence*: the three constituents have different half-lives and clearance rates, their combined pharmacokinetics have never been characterized, and no controlled study has tested the combination in any species [1]. Every claim of synergy is a mechanistic argument. Additionally, the pro-angiogenic properties of both BPC-157 and TB-500/thymosin beta-4 carry a theoretical concern for people with active or recent cancer, and the TB-500 component imposes a clear WADA prohibition [1][3].

Reading them together, the lesson is consistent: the more precisely characterized molecule (GHK-Cu) has the better evidence base; the combination built around it (GLOW) multiplies both the rationale and the unanswered questions.

---

Every claim on this desk is sourced to the peer-reviewed literature and labeled by the model in which it was observed — a literature digest where curiosity and rigor hold each other accountable.